Literature DB >> 7670937

Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors.

J Levenson1, P Giral, M Razavian, J Gariepy, A Simon.   

Abstract

Fibrinogen may play an active role in the development and progression of atherosclerotic plaques. We assessed the association between fibrinogen levels and atherosclerotic plaques over three different arterial sites in an asymptomatic never-treated male population with increased cardiovascular risk. We included 652 men aged 40 to 60 years old with at least one of the following cardiovascular risk factors: cholesterol > 6.2 mmol/L and/or systolic blood pressure > or = 160 mm Hg and/or diastolic blood pressure > or = 95 mm Hg, and/or because they smoked. Carotid and femoral arteries and the abdominal aorta were assessed by using ultrasonographic methods for the presence of plaque, and subjects were categorized according to the presence (or absence) and extent (one versus two or three sites) of plaque. Plasma fibrinogen was measured according to the thrombin-time method of Clauss. While the presence of atherosclerosis was significantly related to age, current smoking, systolic pressure, LDL cholesterol, and fibrinogen levels, the extent of atherosclerosis was related to age and triglyceride and fibrinogen levels. Multiple regression analysis indicated independent associations between fibrinogen and the presence and extent of atherosclerosis. Plaque prevalence was significantly more pronounced with increasing tertile of fibrinogen levels. The odds ratio of the upper to lower fibrinogen tertiles for the presence of plaque was 1.6 (95% confidence interval, 1.4 to 1.8) and 1.4 (95% confidence interval, 1.2 to 1.7) for its extent. Adjustment for other risk factors slightly reduced the association between fibrinogen and atherosclerosis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7670937     DOI: 10.1161/01.atv.15.9.1263

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  13 in total

1.  Significant inverse associations of serum n-6 fatty acids with plasma plasminogen activator inhibitor-1.

Authors:  Sunghee Lee; J David Curb; Takashi Kadowaki; Rhobert W Evans; Katsuyuki Miura; Tomoko Takamiya; Chol Shin; Aiman El-Saed; Jina Choo; Akira Fujiyoshi; Teruo Otake; Sayaka Kadowaki; Todd Seto; Kamal Masaki; Daniel Edmundowicz; Hirotsugu Ueshima; Lewis H Kuller; Akira Sekikawa
Journal:  Br J Nutr       Date:  2011-08-16       Impact factor: 3.718

2.  Expanded network of inflammatory markers of atherogenesis: where are we now?

Authors:  Seyed Hesameddin Abbasi; Mohammad Ali Boroumand
Journal:  Open Cardiovasc Med J       Date:  2010-02-23

3.  Control of fibrinogen biosynthesis: role of the FFA/albumin ratio.

Authors:  Laurence Pilgeram
Journal:  Cardiovasc Eng       Date:  2010-06

4.  Effects of acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia.

Authors:  C Otto; K G Parhofer; M M Ritter; W O Richter; P Schwandt
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

5.  Effect of Angiotensin II Type I Receptor Blockade with Valsartan on Carotid Artery Atherosclerosis: A Double Blind Randomized Clinical Trial Comparing Valsartan and Placebo (EFFERVESCENT).

Authors:  Ronnie Ramadan; Saurabh S Dhawan; José Nilo G Binongo; Ayman Alkhoder; Dean P Jones; John N Oshinski; Arshed A Quyyumi
Journal:  Am Heart J       Date:  2016-01-18       Impact factor: 4.749

Review 6.  Iron-induced fibrin in cardiovascular disease.

Authors:  Boguslaw Lipinski; Etheresia Pretorius
Journal:  Curr Neurovasc Res       Date:  2013-08       Impact factor: 1.990

7.  Elevated white cell count in acute coronary syndromes: relationship to variants in inflammatory and thrombotic genes.

Authors:  Connie E Byrne; Anthony Fitzgerald; Christopher P Cannon; Desmond J Fitzgerald; Denis C Shields
Journal:  BMC Med Genet       Date:  2004-06-01       Impact factor: 2.103

8.  Clinical correlation between N-terminal pro-B-type natriuretic peptide and angiographic coronary atherosclerosis.

Authors:  Demóstenes G L Ribeiro; Ricardo P Silva; Daniella R M M Barboza; Roberto C P Lima-Júnior; Ronaldo A Ribeiro
Journal:  Clinics (Sao Paulo)       Date:  2014-06       Impact factor: 2.365

9.  Association of serum immunoglobulin-G to Porphyromonas gingivalis with acute cerebral infarction in the Chinese population.

Authors:  Zheng Zhang; Ning Ma; Youli Zheng; Li Zhang
Journal:  J Indian Soc Periodontol       Date:  2015 Nov-Dec

10.  Model Based Targeting of IL-6-Induced Inflammatory Responses in Cultured Primary Hepatocytes to Improve Application of the JAK Inhibitor Ruxolitinib.

Authors:  Svantje Sobotta; Andreas Raue; Xiaoyun Huang; Joep Vanlier; Anja Jünger; Sebastian Bohl; Ute Albrecht; Maximilian J Hahnel; Stephanie Wolf; Nikola S Mueller; Lorenza A D'Alessandro; Stephanie Mueller-Bohl; Martin E Boehm; Philippe Lucarelli; Sandra Bonefas; Georg Damm; Daniel Seehofer; Wolf D Lehmann; Stefan Rose-John; Frank van der Hoeven; Norbert Gretz; Fabian J Theis; Christian Ehlting; Johannes G Bode; Jens Timmer; Marcel Schilling; Ursula Klingmüller
Journal:  Front Physiol       Date:  2017-10-09       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.